Contact
searchSearch
HMP Global
Login

Psychedelics Topic Center

Cape Cod Symposium Speakers
Overcoming Perception Barriers and Promoting Safe Access to Psychedelics
09/05/2024
Cape Cod Symposium faculty members Raghu Appasani, MD, PC, Gaetano Vaccaro, PhD, CSAT, and Kaci Hohmann, JD, discuss the barriers and opportunities of psychedelic therapy in conventional psychiatric medicine and addiction recovery
Cape Cod Symposium faculty members Raghu Appasani, MD, PC, Gaetano Vaccaro, PhD, CSAT, and Kaci Hohmann, JD, discuss the barriers and opportunities of psychedelic therapy in conventional psychiatric medicine and addiction recovery
Cape Cod Symposium faculty...
09/05/2024
Psychiatry & Behavioral Health
From Psychiatry & Behavioral Health
Cape Cod Symposium Speakers
Q&As
Exploring the Therapeutic Potential of Psychedelic Treatments in Psychiatry
09/05/2024
Cape Cod Symposium faculty members Raghu Appasani, MD, PC, Gaetano Vaccaro, PhD, CSAT, and Kaci Hohmann, JD, explore the therapeutic benefits of psychedelics, how psychedelics function as adjunctive therapies, and key legal considerations.
Cape Cod Symposium faculty members Raghu Appasani, MD, PC, Gaetano Vaccaro, PhD, CSAT, and Kaci Hohmann, JD, explore the therapeutic benefits of psychedelics, how psychedelics function as adjunctive therapies, and key legal considerations.
Cape Cod Symposium faculty...
09/05/2024
Psychiatry & Behavioral Health
From Psychiatry & Behavioral Health
fda building sign
News
FDA Rejection of MDMA-Assisted Therapy for PTSD Divides Psychedelic Stakeholders
08/16/2024
Brionna Mendoza
The US Food and Drug Administration (FDA) last week rejected the new drug application (NDA) from Lykos Therapeutics for midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD) in conjunction with...
The US Food and Drug Administration (FDA) last week rejected the new drug application (NDA) from Lykos Therapeutics for midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD) in conjunction with...
The US Food and Drug...
08/16/2024
Psych Congress Network
Secondary Analysis Shows Which Patients With TRD Benefit Most From Ketamine
News
Secondary Analysis Shows Which Patients With TRD Benefit Most From Ketamine
07/24/2024
Jolynn Tumolo
Ketamine was associated with greater treatment response than electroconvulsive therapy in patients with nonpsychotic treatment-resistant depression who had moderately severe or severe pretreatment symptoms and who initiated treatment as...
Ketamine was associated with greater treatment response than electroconvulsive therapy in patients with nonpsychotic treatment-resistant depression who had moderately severe or severe pretreatment symptoms and who initiated treatment as...
Ketamine was associated with...
07/24/2024
Psych Congress Network
andrew penn
Videos
Decoding the FDA Committee's Decision to Reject MDMA-Assisted Therapy: Part 2
07/01/2024
Andrew Penn, RN, MS, NP, CNS, APRN-BC
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP,...
07/01/2024
Psych Congress Network
andrew penn
Videos
Decoding the FDA Committee's Decision to Reject MDMA-Assisted Therapy With Andrew Penn, MS, PMHNP
06/21/2024
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP,...
06/21/2024
Psych Congress Network
FDA
News
FDA Advisory Committee Rejects First MDMA Treatment for PTSD
06/06/2024
Meagan Thistle
FDA committee rejected an MDMA-based therapy for adult PTSD treatment due to concerns about its effectiveness and the reliability of the data, despite positive study results.
FDA committee rejected an MDMA-based therapy for adult PTSD treatment due to concerns about its effectiveness and the reliability of the data, despite positive study results.
FDA committee rejected an...
06/06/2024
Psych Congress Network
ketamine brain image
News
Study Findings Support Esketamine and Psilocybin as Effective TRD Treatments
05/14/2024
Meagan Thistle
To address the challenges and “inadequate outcomes” with monoamine-based therapies, a Toronto-based research team investigated novel alternatives for TRD.
To address the challenges and “inadequate outcomes” with monoamine-based therapies, a Toronto-based research team investigated novel alternatives for TRD.
To address the challenges and...
05/14/2024
Psych Congress Network
News
CPT III Codes for Psychedelic-Assisted Therapies Take Effect
01/05/2024
Tom Valentino
The temporary codes, which went into effect this week, allow providers to seek coverage and reimbursement for delivery of psychedelic-assisted therapies, pending their approval by the FDA.
The temporary codes, which went into effect this week, allow providers to seek coverage and reimbursement for delivery of psychedelic-assisted therapies, pending their approval by the FDA.
The temporary codes, which went...
01/05/2024
Psych Congress Network
News
MAPS PBC Submits New Drug Application for MDMA-Assisted Therapy for PTSD
12/12/2023
MAPS Public Benefit Corporation’s new drug application to the US Food and Drug Administration for the use of MDMA in combination with psychotherapy to treat post-traumatic stress disorder is the first filing to the FDA for any...
MAPS Public Benefit Corporation’s new drug application to the US Food and Drug Administration for the use of MDMA in combination with psychotherapy to treat post-traumatic stress disorder is the first filing to the FDA for any...
MAPS Public Benefit...
12/12/2023
Psych Congress Network
News
Use of Psilocbyin in Bipolar II Treatment Clinical Trial Produces Strong Results
12/12/2023
Tom Valentino
In a recent trial conducted by Sheppard Pratt researchers, 80% of participants with treatment-resistant bipolar II met the criteria for remission 12 weeks after treatment that included psilocybin and therapy.
In a recent trial conducted by Sheppard Pratt researchers, 80% of participants with treatment-resistant bipolar II met the criteria for remission 12 weeks after treatment that included psilocybin and therapy.
In a recent trial conducted by...
12/12/2023
Psych Congress Network

News Articles

fda building sign
News
FDA Rejection of MDMA-Assisted Therapy for PTSD Divides Psychedelic Stakeholders
08/16/2024
Brionna Mendoza
The US Food and Drug Administration (FDA) last week rejected the new drug application (NDA) from Lykos Therapeutics for midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD) in conjunction with...
The US Food and Drug Administration (FDA) last week rejected the new drug application (NDA) from Lykos Therapeutics for midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD) in conjunction with...
The US Food and Drug...
08/16/2024
Psych Congress Network
Secondary Analysis Shows Which Patients With TRD Benefit Most From Ketamine
News
Secondary Analysis Shows Which Patients With TRD Benefit Most From Ketamine
07/24/2024
Jolynn Tumolo
Ketamine was associated with greater treatment response than electroconvulsive therapy in patients with nonpsychotic treatment-resistant depression who had moderately severe or severe pretreatment symptoms and who initiated treatment as...
Ketamine was associated with greater treatment response than electroconvulsive therapy in patients with nonpsychotic treatment-resistant depression who had moderately severe or severe pretreatment symptoms and who initiated treatment as...
Ketamine was associated with...
07/24/2024
Psych Congress Network
FDA
News
FDA Advisory Committee Rejects First MDMA Treatment for PTSD
06/06/2024
Meagan Thistle
FDA committee rejected an MDMA-based therapy for adult PTSD treatment due to concerns about its effectiveness and the reliability of the data, despite positive study results.
FDA committee rejected an MDMA-based therapy for adult PTSD treatment due to concerns about its effectiveness and the reliability of the data, despite positive study results.
FDA committee rejected an...
06/06/2024
Psych Congress Network
ketamine brain image
News
Study Findings Support Esketamine and Psilocybin as Effective TRD Treatments
05/14/2024
Meagan Thistle
To address the challenges and “inadequate outcomes” with monoamine-based therapies, a Toronto-based research team investigated novel alternatives for TRD.
To address the challenges and “inadequate outcomes” with monoamine-based therapies, a Toronto-based research team investigated novel alternatives for TRD.
To address the challenges and...
05/14/2024
Psych Congress Network
News
CPT III Codes for Psychedelic-Assisted Therapies Take Effect
01/05/2024
Tom Valentino
The temporary codes, which went into effect this week, allow providers to seek coverage and reimbursement for delivery of psychedelic-assisted therapies, pending their approval by the FDA.
The temporary codes, which went into effect this week, allow providers to seek coverage and reimbursement for delivery of psychedelic-assisted therapies, pending their approval by the FDA.
The temporary codes, which went...
01/05/2024
Psych Congress Network
News
MAPS PBC Submits New Drug Application for MDMA-Assisted Therapy for PTSD
12/12/2023
MAPS Public Benefit Corporation’s new drug application to the US Food and Drug Administration for the use of MDMA in combination with psychotherapy to treat post-traumatic stress disorder is the first filing to the FDA for any...
MAPS Public Benefit Corporation’s new drug application to the US Food and Drug Administration for the use of MDMA in combination with psychotherapy to treat post-traumatic stress disorder is the first filing to the FDA for any...
MAPS Public Benefit...
12/12/2023
Psych Congress Network
News
Use of Psilocbyin in Bipolar II Treatment Clinical Trial Produces Strong Results
12/12/2023
Tom Valentino
In a recent trial conducted by Sheppard Pratt researchers, 80% of participants with treatment-resistant bipolar II met the criteria for remission 12 weeks after treatment that included psilocybin and therapy.
In a recent trial conducted by Sheppard Pratt researchers, 80% of participants with treatment-resistant bipolar II met the criteria for remission 12 weeks after treatment that included psilocybin and therapy.
In a recent trial conducted by...
12/12/2023
Psych Congress Network
News
Microdosing Associated With Increased Mindfulness, Lower Neuroticism in ADHD Patients
11/28/2023
Tom Valentino
A study conducted by researchers in the Netherlands has found that microdosing psychedelics for 4 weeks induced an increase in mindfulness and a decrease in neuroticism among adults diagnosed with attention-deficit/hyperactivity disorder...
A study conducted by researchers in the Netherlands has found that microdosing psychedelics for 4 weeks induced an increase in mindfulness and a decrease in neuroticism among adults diagnosed with attention-deficit/hyperactivity disorder...
A study conducted by researchers...
11/28/2023
Psych Congress Network
News
Compass Pathways Initiates Phase 3 Study of Psilocybin for Treatment-Resistant Depression
11/27/2023
Tom Valentino
Compass Pathways, which recently opened a new research center in London, has begun a multi-site study of investigational psilocybin treatment of treatment-resistant depression.
Compass Pathways, which recently opened a new research center in London, has begun a multi-site study of investigational psilocybin treatment of treatment-resistant depression.
Compass Pathways, which recently...
11/27/2023
Psych Congress Network
Christopher Nicholas, PhD
News
Psychedelics Show Potential to Improve SUD Treatment Outcomes
10/31/2023
Tom Valentino
With drug overdose deaths continuing to climb, Sana Symposium presenter Christopher Nicholas, PhD, said studies suggest that incorporating the use of psychedelics into treatment modalities could improve outcomes.
With drug overdose deaths continuing to climb, Sana Symposium presenter Christopher Nicholas, PhD, said studies suggest that incorporating the use of psychedelics into treatment modalities could improve outcomes.
With drug overdose deaths...
10/31/2023
Psych Congress Network
US FDA building
News
FDA Requests Removal of Suicide Risk Warnings From GLP-1 RA Labels
01/14/2026
Maria Mantas
The US Food and Drug Administration (FDA) has requested the removal of information regarding the risk of suicidal ideation and behaviors (SI/B) from the labeling of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications.
The US Food and Drug Administration (FDA) has requested the removal of information regarding the risk of suicidal ideation and behaviors (SI/B) from the labeling of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications.
The US Food and Drug...
01/14/2026
Psych Congress Network
illustration of a brain
News
Meta-Analysis Confirms Processing Speed as Core Cognitive Deficit in Schizophrenia
01/12/2026
Maria Mantas
Processing speed remains one of the most severely impaired cognitive domains in people with schizophrenia, according to a large systematic review and meta-analysis published in JAMA Psychiatry.
Processing speed remains one of the most severely impaired cognitive domains in people with schizophrenia, according to a large systematic review and meta-analysis published in JAMA Psychiatry.
Processing speed remains one of...
01/12/2026
Psych Congress Network
FDA building
News
FDA Approves At-Home Neuromodulation Therapy Device for Major Depression
01/12/2026
Maria Mantas
The US Food and Drug Administration has approved Proliv™Rx, a novel at-home neuromodulation therapy as adjunctive treatment for adults with major depressive disorder (MDD).
The US Food and Drug Administration has approved Proliv™Rx, a novel at-home neuromodulation therapy as adjunctive treatment for adults with major depressive disorder (MDD).
The US Food and Drug...
01/12/2026
Psych Congress Network
woman on a hill
News
Delay Discounting Fails to Predict Antidepressant Relapse in MDD
01/09/2026
Maria Mantas
A new multi-site study suggests that while delay discounting is elevated in patients with remitted MDD, it neither changes after antidepressant medication discontinuation nor predicts subsequent depressive relapse.
A new multi-site study suggests that while delay discounting is elevated in patients with remitted MDD, it neither changes after antidepressant medication discontinuation nor predicts subsequent depressive relapse.
A new multi-site study suggests...
01/09/2026
Psych Congress Network
An illustration of a brain
News
Disease Duration, Antipsychotic Use, and Brain Aging in Schizophrenia
01/06/2026
Sarah Fleming
In a study published in Schizophrenia Research, investigators examined whether disease duration or antipsychotic exposure explains increases in brain age among patients with schizophrenia using MRI-based machine-learning models.
In a study published in Schizophrenia Research, investigators examined whether disease duration or antipsychotic exposure explains increases in brain age among patients with schizophrenia using MRI-based machine-learning models.
In a study published in...
01/06/2026
Psych Congress Network
Two pill bottles tipped over with pills on a table
News
Adolescent SSRI Use Not Causally Linked to Bipolar Disorder Risk, UK Registry Study Finds
01/06/2026
Sarah Fleming
New research published in BMJ Mental Health leveraged national United Kingdom (UK) health registry data to investigate whether selective serotonin reuptake inhibitor (SSRI) treatment in adolescents with unipolar depression influences later...
New research published in BMJ Mental Health leveraged national United Kingdom (UK) health registry data to investigate whether selective serotonin reuptake inhibitor (SSRI) treatment in adolescents with unipolar depression influences later...
New research published in BMJ...
01/06/2026
Psych Congress Network
artificial intelligence
News
AI-Based Prediction Tool Flags Psychotic and Bipolar Disorder Risk
01/05/2026
Maria Mantas
A large UK study reports that an artificial intelligence (AI)–enabled clinical prediction model may accurately identify individuals at risk of developing psychotic disorders or bipolar disorders.
A large UK study reports that an artificial intelligence (AI)–enabled clinical prediction model may accurately identify individuals at risk of developing psychotic disorders or bipolar disorders.
A large UK study reports that an...
01/05/2026
Psych Congress Network
a group of clinicians
News
Collaborative Care Shows No Added Benefit for OUD With Depression or PTSD
01/02/2026
Maria Mantas
A collaborative care model tailored for low-resource primary care settings did not improve outcomes beyond enhanced usual care for adults with OUD and co-occurring depression and/or PTSD.
A collaborative care model tailored for low-resource primary care settings did not improve outcomes beyond enhanced usual care for adults with OUD and co-occurring depression and/or PTSD.
A collaborative care model...
01/02/2026
Psych Congress Network
A woman with insomnia lying in bed trying to sleep
News
Sleep and Psychiatric Disorders: Shared Mechanisms and Clinical Relevance
01/02/2026
Sarah Fleming
A narrative review in PLOS Mental Health synthesizes evidence on the bidirectional relationship between sleep and psychiatric disorders and highlights shared neurobiological mechanisms that span major depression, bipolar disorder (BD),...
A narrative review in PLOS Mental Health synthesizes evidence on the bidirectional relationship between sleep and psychiatric disorders and highlights shared neurobiological mechanisms that span major depression, bipolar disorder (BD),...
A narrative review in PLOS...
01/02/2026
Psych Congress Network
A person's hands typing on a smartphone
News
Smartphone-Delivered Digital CBT Improves Anxiety Symptoms in Adults
12/29/2025
Sarah Fleming
A smartphone-delivered digital cognitive behavioral therapy (DCBT) program significantly improved symptoms of generalized anxiety disorder (GAD) in adults, according to a randomized clinical trial published in JAMA Network Open.
A smartphone-delivered digital cognitive behavioral therapy (DCBT) program significantly improved symptoms of generalized anxiety disorder (GAD) in adults, according to a randomized clinical trial published in JAMA Network Open.
A smartphone-delivered digital...
12/29/2025
Psych Congress Network

Blogs

Perspectives
Ketamine Shows Promise in Treatment of Mental Health, Chronic Pain, Addiction
04/12/2021
Steven L. Mandel, MD
A report published by CDC in August 2020 showed huge increases in mental health issues during the time period April-June 2020 compared with the same time period the previous year. Instances of suicidal conditions increased 200%, anxiety...
A report published by CDC in August 2020 showed huge increases in mental health issues during the time period April-June 2020 compared with the same time period the previous year. Instances of suicidal conditions increased 200%, anxiety...
A report published by CDC in...
04/12/2021
Addiction Professional
Blog
Psychedelics in Group Therapy for HIV Survivors Shows Promising Results
10/02/2020
Andrew Penn, RN, MS, NP, CNS, APRN-BC
BLOG: In a recent study, the utilization of psychedelic medicine in group therapy was linked with reduced demoralization among long-term, gay-identified, male HIV survivors—an outcome with larger implications for overall healthcare.
BLOG: In a recent study, the utilization of psychedelic medicine in group therapy was linked with reduced demoralization among long-term, gay-identified, male HIV survivors—an outcome with larger implications for overall healthcare.
BLOG: In a recent study, the...
10/02/2020
Psych Congress Network
Blog
Psych Congress to Bring Psychedelic-Assisted Therapies Into Focus
09/03/2020
Andrew Penn, RN, MS, NP, CNS, APRN-BC
BLOG: Psychedelic-assisted therapies, once consigned to the fringes of psychiatric practice, are exploding into the mainstream of psychiatry and will take center stage at a Psych Congress preconference.
BLOG: Psychedelic-assisted therapies, once consigned to the fringes of psychiatric practice, are exploding into the mainstream of psychiatry and will take center stage at a Psych Congress preconference.
BLOG: Psychedelic-assisted...
09/03/2020
Psych Congress Network
Blog
Psychedelics and Wellness: What’s the Connection?
12/17/2019
Andrew Penn, RN, MS, NP, CNS, APRN-BC
BLOG: I sat down with Saundra Jain, MA, PsyD, LPC to better understand the connection between wellness and psychedelics.
BLOG: I sat down with Saundra Jain, MA, PsyD, LPC to better understand the connection between wellness and psychedelics.
BLOG: I sat down with Saundra...
12/17/2019
Psych Congress Network
Blog
The Psychedelic Aspect of Esketamine is an Opportunity, Not a Side Effect
05/23/2019
Andrew Penn, RN, MS, NP, CNS, APRN-BC
BLOG: Esketamine represents the first psychedelic treatment approved by the FDA for a psychiatric condition.
BLOG: Esketamine represents the first psychedelic treatment approved by the FDA for a psychiatric condition.
BLOG: Esketamine represents the...
05/23/2019
Psych Congress Network
Blog
A Turning Point for Psychedelics?
06/06/2018
Andrew Penn, RN, MS, NP, CNS, APRN-BC
BLOG: Michael Pollan, author of The Omnivore’s Dilemma and The Botany of Desire, has turned his spotlight of curiosity onto the subject of psychedelics with his new book How to Change Your Mind.
BLOG: Michael Pollan, author of The Omnivore’s Dilemma and The Botany of Desire, has turned his spotlight of curiosity onto the subject of psychedelics with his new book How to Change Your Mind.
BLOG: Michael Pollan, author of...
06/06/2018
Psych Congress Network
Blog
Depression as Disconnection: New Lessons From Psychedelic Psychotherapy Studies
11/02/2017
Andrew Penn, RN, MS, NP, CNS, APRN-BC
BLOG: Recent qualitative studies on subjects treated with psilocybin may begin to help us understand the subjective experience caused by the drug that may lead to its antidepressant effects.
BLOG: Recent qualitative studies on subjects treated with psilocybin may begin to help us understand the subjective experience caused by the drug that may lead to its antidepressant effects.
BLOG: Recent qualitative studies...
11/02/2017
Psych Congress Network
Blog
Psilocybin Studies: A New Ray of Hope for Psychiatry?
12/01/2016
Andrew Penn, RN, MS, NP, CNS, APRN-BC
BLOG: These studies were the latest findings showing that psychedelics, erroneously dismissed as mere intoxicants and swept up in the hysteria of the Nixon-era drug wars, could prove to be as important to psychiatry as penicillin was to...
BLOG: These studies were the latest findings showing that psychedelics, erroneously dismissed as mere intoxicants and swept up in the hysteria of the Nixon-era drug wars, could prove to be as important to psychiatry as penicillin was to...
BLOG: These studies were the...
12/01/2016
Psych Congress Network
Blog
Psychedelics: What to Tell Patients Today
08/25/2015
Andrew Penn, RN, MS, NP, CNS, APRN-BC
Psychedelic compounds are powerful, and they have great potential to help patients with intractable conditions. Yet any compound with that kind of power also has the potential to harm, and that harm should not be trivialized.
Psychedelic compounds are powerful, and they have great potential to help patients with intractable conditions. Yet any compound with that kind of power also has the potential to harm, and that harm should not be trivialized.
Psychedelic compounds are...
08/25/2015
Psych Congress Network
Blog
How Psychedelics May Be Used to Accelerate Psychotherapy
08/19/2015
Andrew Penn, RN, MS, NP, CNS, APRN-BC
Personal reports from treatment subjects are as compelling as the quantitative data.
Personal reports from treatment subjects are as compelling as the quantitative data.
Personal reports from treatment...
08/19/2015
Psych Congress Network
marc agronin md
Faculty Insights
Alzheimer Disease Prevention: Part 2
07/29/2024
Marc E. Agronin, MD
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated...
07/29/2024
Psych Congress Network
Rakesh Amin, MD.
Blog
Treating Schizophrenia: The Importance of Early Identification and Intervention
06/13/2023
Rakesh Amin, MD
Rakesh Amin, MD, discusses the importance of partnering with patients and caregivers to set treatment goals and the importance of introducing long-acting injectables earlier in the treatment of schizophrenia.
Rakesh Amin, MD, discusses the importance of partnering with patients and caregivers to set treatment goals and the importance of introducing long-acting injectables earlier in the treatment of schizophrenia.
Rakesh Amin, MD, discusses the...
06/13/2023
Psych Congress Network
Marc Agronin, MD.
Blog
Alzheimer Disease Prevention
08/30/2022
Marc E. Agronin, MD
Psych Congress Network Section Editor Mark Agronin, MD, provides expert clinical insights on reducing the risk for Alzheimer disease and delaying its onset and progression.
Psych Congress Network Section Editor Mark Agronin, MD, provides expert clinical insights on reducing the risk for Alzheimer disease and delaying its onset and progression.
Psych Congress Network Section...
08/30/2022
Psych Congress Network
Ed Jones, PhD
Blog
How Our Clinicians Can Help Fix the US Health Care System
07/28/2022
Ed Jones, PhD
Ed Jones, PhD, discusses the need for a clinical refocusing that includes broad access to psychosocial solutions and ensuring socially informed clinicians can help underserved communities.
Ed Jones, PhD, discusses the need for a clinical refocusing that includes broad access to psychosocial solutions and ensuring socially informed clinicians can help underserved communities.
Ed Jones, PhD, discusses the...
07/28/2022
Psych Congress Network
Ed Jones, PhD
Perspective
The Universal Behavior Model: A Comprehensive Approach to Integrated Care
07/21/2022
Ed Jones, PhD
Ed Jones, PhD: "We miss this psychosocial aspect of care today...What is missing?  We need psychotherapists based in primary care, often focused on mundane issues rather than the complexities of diagnosis or treatment."
Ed Jones, PhD: "We miss this psychosocial aspect of care today...What is missing?  We need psychotherapists based in primary care, often focused on mundane issues rather than the complexities of diagnosis or treatment."
Ed Jones, PhD: "We miss this...
07/21/2022
Psych Congress Network
Chan_Khan_Digital Mental Health
Blog
Who will use it? How to Get Digital Mental Health Apps Into the Hands of Patients
04/27/2022
Steven Chan, MD, MBA, and Burhan Ahmed Khan, MD, discuss how to encourage patients to use digital mental health apps.
Steven Chan, MD, MBA, and Burhan Ahmed Khan, MD, discuss how to encourage patients to use digital mental health apps.
Steven Chan, MD, MBA, and Burhan...
04/27/2022
Psychiatry & Behavioral Health
Chan_Khan_Digital Mental Health
Blog
How to Navigate Quality Issues With Mental Health Apps
04/21/2022
Steven Chan, MD, MBA, and Burhan Ahmed Khan, MD, navigating quality issues with digital mental health applications.
Steven Chan, MD, MBA, and Burhan Ahmed Khan, MD, navigating quality issues with digital mental health applications.
Steven Chan, MD, MBA, and Burhan...
04/21/2022
Psychiatry & Behavioral Health
Andrew Penn, RN, MS, NP, CNS, APRN-BC
Blog
How New NPs Can Find Mentors
03/04/2022
Andrew Penn, RN, MS, NP, CNS, APRN-BC
Andrew Penn, NP, explains mentoring, how to find one as an NP, and what to do when you have found a possible mentor. He gives practical advice, questions to ask, and avenues to find the right fit.
Andrew Penn, NP, explains mentoring, how to find one as an NP, and what to do when you have found a possible mentor. He gives practical advice, questions to ask, and avenues to find the right fit.
Andrew Penn, NP, explains...
03/04/2022
Psych Congress Network
Julie Bailey
Blog
How to Be a Safe Space for Someone
02/08/2022
In this blog, Julie Bailey, LCPC, shares her insights on providing a safe space for patients to discuss these social anxieties, as well as tips to share with patients about slowly reintegrating into life after COVID-19.
In this blog, Julie Bailey, LCPC, shares her insights on providing a safe space for patients to discuss these social anxieties, as well as tips to share with patients about slowly reintegrating into life after COVID-19.
In this blog, Julie Bailey,...
02/08/2022
Psych Congress Network
major depressive disorder
Blog
The Best and Worst Changes Brought On By the Pandemic
01/31/2022
Mental health advocate, Dorothy Watson shares her insights about the impact the pandemic has had on mental health and where we go from here.
Mental health advocate, Dorothy Watson shares her insights about the impact the pandemic has had on mental health and where we go from here.
Mental health advocate, Dorothy...
01/31/2022
Psych Congress Network

Interactive Features

Quiz
Quiz: Psilocybin Named Breakthrough Therapy for Which Condition?
12/10/2019
The US Food and Drug Administration (FDA) recently gave the Breakthrough Therapy designation to psilocybin for the treatment of which mental health condition?
The US Food and Drug Administration (FDA) recently gave the Breakthrough Therapy designation to psilocybin for the treatment of which mental health condition?
The US Food and Drug...
12/10/2019
Psych Congress Network
Mark Olfson, MD, MPH
Quiz
Telemental Health Use Patterns
01/16/2026
Maria Mantas
Are you caught up with the latest research on telehealth use patterns?
Are you caught up with the latest research on telehealth use patterns?
Are you caught up with the...
01/16/2026
Psych Congress Network
illustration of a laptop screen displaying a test
Quiz
Stimulants and Psychosis Risk in ADHD
12/22/2025
Maria Mantas
Do you remember the findings from this systematic review?
Do you remember the findings from this systematic review?
Do you remember the findings...
12/22/2025
Psych Congress Network
Joseph Goldberg, MD
Quiz
Diagnosing Mixed Features in Bipolar Disorder
12/03/2025
Joseph F. Goldberg, MD
Test your knowledge with this quick quiz!
Test your knowledge with this quick quiz!
Test your knowledge with this...
12/03/2025
Psych Congress Network
Pop quiz written on a blackboard with white chalk
Quiz
Depression, Inflammation, and Insomnia
11/19/2025
Brionna Mendoza
Test your knowledge with this quiz!
Test your knowledge with this quiz!
Test your knowledge with this...
11/19/2025
Psych Congress Network
quiz
Quiz
Early Lead Exposure and Mental Health Outcomes
11/10/2025
Maria Mantas
Test your knowledge with this quick quiz!
Test your knowledge with this quick quiz!
Test your knowledge with this...
11/10/2025
Psych Congress Network
a teenager's hand putting a bag of white pills into another teenager's hand.
Quiz
Test Your Knowledge – Understanding Abuse Potential Across ADHD Therapies: What Clinicians Need to Know
10/23/2025
Curb misuse before it starts—test your diversion-prevention game in 3 quick questions.
Curb misuse before it starts—test your diversion-prevention game in 3 quick questions.
Curb misuse before it...
10/23/2025
Psych Congress Network
Edward Kaftarian, MD
Quiz
Building Patient Rapport in Telepsychiatry
10/09/2025
Edward Kaftarian, MD
Do you remember Dr Kaftarian's recommended strategies for building patient rapport via telehealth?
Do you remember Dr Kaftarian's recommended strategies for building patient rapport via telehealth?
Do you remember Dr Kaftarian's...
10/09/2025
Psych Congress Network
A woman sleeping peacefully
Quiz
Test Your Knowledge – ADHD and Sleep: Why Non-Stimulants Might Be the Right Choice (Part 3)
10/09/2025
Sleep and ADHD intersect—see if your management playbook is up to date in 3 quick questions.
Sleep and ADHD intersect—see if your management playbook is up to date in 3 quick questions.
Sleep and ADHD intersect—see if...
10/09/2025
Psych Congress Network
Blocks that spell ADHD with pills and a stethoscope
Quiz
Test Your Knowledge – The Rise of Non-Stimulant ADHD Treatments: A Paradigm Shift?
10/08/2025
Rethink ADHD beyond stimulants—test your non-stimulant savvy with 3 quick questions.
Rethink ADHD beyond stimulants—test your non-stimulant savvy with 3 quick questions.
Rethink ADHD beyond...
10/08/2025
Psych Congress Network
A boy sleeping peacefully.
Quiz
Test Your Knowledge – ADHD and Sleep: Why Non-Stimulants Might Be the Right Choice (Part 2)
09/29/2025
How well do you know the evidence on ADHD and sleep? Take this quick quiz to find out.
How well do you know the evidence on ADHD and sleep? Take this quick quiz to find out.
How well do you know the...
09/29/2025
Psych Congress Network

Posters

Residual Symptom Burden in Patients With Narcolepsy Satisfied With Treatment: Subgroup Analysis From The CRESCENDO Survey
CRESCENDO was a survey of the patient experience in adults with narcolepsy type 1. This subgroup analysis examined residual symptoms among respondents who reported satisfaction with curre...
10/17/2025
Improvement in Bothersome Mood, Cognitive, and Functional Impacts of Idiopathic Hypersomnia After Low-Sodium Oxybate Treatment in the DUET Study
Jazz DUET (NCT05875974) was a patient-centric, prospective, single-arm, open-label study evaluating effectiveness of low-sodium oxybate (LXB) in IH or narcolepsy. In participants with IH,...
10/17/2025
Neuropsychiatric and Cognitive Sequelae of Severe Hypothyroidism: Insights into Endocrine–Brain Interactions
Severe hypothyroidism can present with predominant psychiatric and cognitive symptoms, making diagnosis challenging when classic somatic signs are absent. This poster explores the neurops...
10/17/2025
Late-Onset Agitated Depression with Anxious and Obsessive Features Triggered by Parental Decline: A Case for Integrated Pharmacology, Neuromodulation, and Psychodynamic Treatments
A 65-year-old male veteran with no prior psychiatric history and a past medical history of seizure disorder developed severe, treatment-resistant depression after witnessing his mother’s ...
10/17/2025
Pilot Implementation Of Mindfulness Meditation With Esketamine For Major Depressive Disorder
This project explores the integration of mindfulness meditation with esketamine in the treatment of major depressive disorder. Conducted as a quasi-experimental pilot, the study involved ...
10/17/2025
Retrospective Analysis of Real-World Transition Strategies for Xanomeline and Trospium Chloride in Adult Patients With Schizophrenia
Up to 50% of adults with schizophrenia switch antipsychotic medication within 2 years of treatment initiation. We conducted a real-world analysis of strategies used by healthcare provider...
10/17/2025
Real-World Comparison of Olanzapine/Samidorphan vs Olanzapine: An Assessment of Treatment Patterns and Acute Care Events Among Patients With Bipolar I Disorder
This real-world claims analysis compared combined olanzapine/samidorphan (OLZ/SAM) versus olanzapine in patients with bipolar I disorder. OLZ/SAM was associated with significantly better ...
10/17/2025
Results From a Phase 4, Open-Label, Multicenter, Two-Cohort, Two-Period, Slow-Titration and Food Effect Trial to Assess the Safety and Efficacy of Xanomeline and Trospium Chloride in Schizophrenia
Short description: Prior pharmacokinetic studies of X/T in healthy volunteers showed dosing with food reduced trospium bioavailability, potentially impacting tolerability. This open-label...
10/17/2025
Long-Term Effectiveness With Subcutaneous Long-Acting Injectable Olanzapine (TV-44749) in Adults With Schizophrenia: Results From up to 48 Weeks Open Label Treatment in the Phase 3 SOLARIS Trial
TV-44749 is a once-monthly subcutaneous long-acting injectable olanzapine, designed to provide sustained efficacy without the risk of post-injection delirium/sedation syndrome (PDSS). Her...
10/17/2025
Montgomery-Åsberg Depression Rating Scale Anhedonia Factor Score Following Esketamine Nasal Spray Monotherapy in Adult Patients With Treatment-Resistant Depression: A Post Hoc Analysis
This post hoc analysis of a randomized double-blind study (NCT04599855) evaluated changes in the 5-item Montgomery-Åsberg Depression Rating Scale anhedonia factor score (a composite of it...
10/17/2025

E-Learning

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, MSN, APRN, PMHNP-BC
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use